 |
 |
 |
||
|
||||
 |
|
| Updated Sep. 1, 2010 |
|
||||||||
 |
|
 |
|
 |
|
 |
|
 |
|
||||||||
| |
|
New Guidelines Issued for Clostridium difficile
ISSUE: SEPTEMBER, 2010 A panel of experts representing several medical specialties has issued new guidelines for diagnosing, managing and treating Clostridium difficile infection (CDI) in adults. The guidelines, which were published in Infection Control and Hospital Epidemiology (2010;31:431-455, PMID: 20307191), update recommendations published more than 15 years ago when CDI incidence was much lower than it is today, the strains less virulent, and the decreased effectiveness of metronidazole was not yet known. read more | |
|
Investigational Agent Stops Potentially Fatal 5-FU Toxicity
ISSUE: JULY, 2010 Uridine triacetate, an investigational, orally administered drug, is an effective, lifesaving antidote for 5-fluorouracil toxicity, according to a new study reported at the 2010 annual meeting of the American Society of Clinical Oncology. read more | |
|
Concern Revving Up Over REMS For ESAs
ISSUE: JUNE, 2010 Oncologists are struggling to comply with requirements imposed by the FDA’s Risk Evaluation and Mitigation Strategy (REMS) program for erythropoietin- stimulating agents (ESAs). read more | |
|
Cost Analysis for End-Stage Cancer Pain: Intrathecal Therapy More Affordable Than Opioids
ISSUE: JUNE, 2010 A cost analysis of implanted intrathecal therapy versus long-acting opioids for patients with end-stage cancer pain has shown that intrathecal pumps are less costly than comprehensive medical management over a patient’s last year of life. read more | |
|
Breakthrough Pain Significant for Many Cancer Patients
ISSUE: APRIL, 2010 Breakthrough pain inflicts a heavy toll on the quality of life of cancer patients and cancer survivors, according to a survey commissioned by the American Pain Foundation. read more | |
|
Managing Cancer Pain, One Patient at a Time
ISSUE: APRIL, 2010 Recent studies reveal that nearly one-third of cancer patients nationwide—approximately 3 million to 5 million people—suffer moderate to severe pain, regardless of the stage of their disease. Those with advanced cancer experience severe pain 90% of the time—yet only about one-half of all cancer patients receive adequate pain management. read more | |
|
Treating the Side Effects of AI Therapy
ISSUE: APRIL, 2010 Vitamin D and testosterone may help ameliorate muscle and joint pain associated with aromatase inhibitor use. These are the findings from two small studies presented at the San Antonio Breast Cancer Symposium. read more | |
|
Will New Therapies Replace Warfarin/Heparin for VTE?
ISSUE: MARCH, 2010 A series of Phase III studies suggest that the vitamin K antagonist warfarin will be largely or completely replaced by newer oral therapies that provide at least comparable protection against venous thromboembolism, but without the need for laboratory monitoring. read more |
| home | about us | advertise | contact | publications |